[go: up one dir, main page]

DE60123031D1 - Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets - Google Patents

Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets

Info

Publication number
DE60123031D1
DE60123031D1 DE60123031T DE60123031T DE60123031D1 DE 60123031 D1 DE60123031 D1 DE 60123031D1 DE 60123031 T DE60123031 T DE 60123031T DE 60123031 T DE60123031 T DE 60123031T DE 60123031 D1 DE60123031 D1 DE 60123031D1
Authority
DE
Germany
Prior art keywords
dry powder
fraction
powder
hartpellets
fine particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123031T
Other languages
English (en)
Other versions
DE60123031T2 (de
Inventor
Nicholas Staniforth
Morton Alexander Vodden
Rajbir Gill
Gaetano Brambilla
Rossella Musa
Lorenzo Ferrarini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60123031(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of DE60123031D1 publication Critical patent/DE60123031D1/de
Application granted granted Critical
Publication of DE60123031T2 publication Critical patent/DE60123031T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60123031T 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets Expired - Lifetime DE60123031T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0009469.8A GB0009469D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formalities for use in inhaler devices
GB0009469 2000-04-17
EP00113608 2000-06-27
EP00113608 2000-06-27
PCT/EP2001/004338 WO2001078693A2 (en) 2000-04-17 2001-04-17 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets

Publications (2)

Publication Number Publication Date
DE60123031D1 true DE60123031D1 (de) 2006-10-26
DE60123031T2 DE60123031T2 (de) 2007-03-08

Family

ID=26071084

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60125344T Expired - Lifetime DE60125344T2 (de) 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen
DE60123031T Expired - Lifetime DE60123031T2 (de) 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets
DE60131265T Revoked DE60131265T2 (de) 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60125344T Expired - Lifetime DE60125344T2 (de) 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60131265T Revoked DE60131265T2 (de) 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren

Country Status (32)

Country Link
US (4) US6884794B2 (de)
EP (6) EP1829533B1 (de)
JP (2) JP2003530425A (de)
KR (1) KR20030069047A (de)
CN (1) CN1424909A (de)
AT (5) ATE513542T1 (de)
AU (3) AU4859501A (de)
BR (3) BR0110139A (de)
CA (3) CA2405767C (de)
CY (1) CY1107315T1 (de)
CZ (1) CZ301904B6 (de)
DE (3) DE60125344T2 (de)
DK (3) DK1276472T3 (de)
DZ (1) DZ3315A1 (de)
EE (1) EE05257B1 (de)
ES (3) ES2272473T3 (de)
GB (2) GB2363987A (de)
HU (4) HUP0300490A2 (de)
IL (1) IL152306A0 (de)
MA (1) MA26892A1 (de)
MX (3) MXPA02010212A (de)
MY (1) MY129384A (de)
NO (4) NO20024971L (de)
NZ (1) NZ521887A (de)
PE (1) PE20011227A1 (de)
PL (3) PL358640A1 (de)
PT (3) PT1274406E (de)
SA (1) SA01220062B1 (de)
SI (2) SI1719505T1 (de)
SK (1) SK284248B6 (de)
TN (1) TNSN01060A1 (de)
WO (3) WO2001078695A2 (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
AU3409399A (en) * 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
WO2002000197A1 (en) * 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
AU2211502A (en) † 2000-11-30 2002-06-11 Vectura Ltd Method of making particles for use in a pharmaceutical composition
ES2708961T3 (es) * 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
PT1337239E (pt) 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
AU2002330390A1 (en) * 2002-03-20 2003-09-29 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
FI116657B (fi) * 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1599209B1 (de) * 2002-08-21 2011-08-17 Norton Healthcare Limited Inhalationszusammensetzung
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (de) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
AU2004231342A1 (en) * 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US7094545B2 (en) * 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
EP1646370A1 (de) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmazeutische formulierungen
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
SI1500390T1 (sl) * 2003-07-25 2006-02-28 Ferring Bv Farmacevtski dezmopresinski sestavek kot trdna dozirna oblika in postopek za njegovo pripravo
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
AU2004294889B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
KR101725225B1 (ko) 2004-04-23 2017-04-12 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
EP3199164B1 (de) 2005-02-10 2020-03-18 Glaxo Group Limited Verfahren zur herstellung von lactose unter verwendung von vorklassifizierungsverfahren sowie damit erzeugte pharmazeutische formulierungen
RU2007137121A (ru) * 2005-03-09 2009-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Частица и препарат, содержащий указанную частицу
US20090298802A1 (en) * 2005-03-30 2009-12-03 Sequeira Joel A Pharmaceutical Compositions
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP1944018A1 (de) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Mikronisierte Partikel mit niedrigdosierten Wirkstoffen für Pulverzubereitungen zur Inhalation
EP2120875B1 (de) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Verfahren zur therapeutischen verabreichung von dhe zur schnellen linderung von migräne bei gleichzeitiger minimierung von nebenwirkungsprofilen
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
WO2009088054A1 (ja) 2008-01-11 2009-07-16 Astellas Pharma Inc. 精巣の疼痛又は不快感行動及び頻尿併発モデル動物
EP2476680B1 (de) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinon)-substituierte Pyrido-Indole
EP2080508A1 (de) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Trockenpulverformulierung mit einem anticholinergischen Arzneimittel
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2191821A1 (de) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Mikropartikel enthaltend ein Salz von 8-Hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone mit verbesserten Adhesionseigenschaften zur Trockenpulver-Inhalation
US8673931B2 (en) 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
PT3578169T (pt) 2009-02-26 2024-07-29 Glaxo Group Ltd Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
EP2421514A2 (de) * 2009-04-24 2012-02-29 Schering Corporation Agglomeratformulierungen für trockenpulver-inhaliergerät
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2360147A1 (de) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Verfahren zur Herstellung von kristallinen Partikeln von einem Salz von 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-chinolinon (Carmoterol)
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
PT2563813E (pt) 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
WO2011152804A2 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations
UA107499C2 (uk) 2010-06-22 2015-01-12 Chiesi Farm Spa Склад сухого порошку, який містить антимускариновий засіб
PE20171256A1 (es) 2010-08-03 2017-08-28 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
WO2012028745A1 (en) * 2010-09-03 2012-03-08 Pharmaterials Limited Pharmaceutical composition suitable for use in a dry powder inhaler
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
KR20140005150A (ko) 2010-09-30 2014-01-14 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제 내 마그네슘 스테아레이트의 용도
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
WO2013109210A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising budesonide
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
EP2804583A1 (de) * 2012-01-16 2014-11-26 Mahmut Bilgic Trockenpulverformulierungen mit r-formoterol als wirkstoff
RS63759B1 (sr) * 2012-01-25 2022-12-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
DK3421042T3 (da) 2012-03-07 2024-07-22 Beyond Air Ltd Indånding af nitrogenoxid til behandling af luftvejssygdomme
CN104284679B (zh) 2012-03-13 2017-08-04 瑞斯比维特有限公司 药物制剂
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US11052202B2 (en) 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
SI2948148T1 (sl) 2013-01-28 2020-12-31 Incozen Therapeutics Pvt. Ltd. Postopki za zdravljenje avtoimunskih, respiratornih in vnetnih obolenj z inhalacijo roflumilast N-oksida
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
TR201802969T4 (tr) * 2013-07-01 2018-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Yeni inhalasyon formülasyonları.
CA2917752C (en) * 2013-07-11 2022-05-03 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
WO2015049519A2 (en) * 2013-10-02 2015-04-09 Vectura Limited Method and apparatus
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
EP2957552B1 (de) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterolformulierungen
TR201818680T4 (tr) * 2014-07-09 2019-01-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
WO2016057693A1 (en) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
WO2016209208A1 (en) * 2015-06-23 2016-12-29 Schlumberger Canada Limited Mobile proppant recognition
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
PL3628331T3 (pl) * 2015-11-16 2021-11-08 Chiesi Farmaceutici S.P.A. Sposób wytwarzania formulacji w postaci suchego proszku zawierającej środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny
GEP20207178B (en) 2015-11-16 2020-11-10 Chiesi Farma Spa Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic
MX2018007512A (es) * 2015-12-24 2018-09-17 Philip Morris Products Sa Capsula de particula de nicotina.
EP3463461A4 (de) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von refraktärer generalisierter myasthenia gravis
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
KR20220155395A (ko) * 2017-05-11 2022-11-22 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
PL3621589T3 (pl) * 2017-05-11 2021-12-06 Chiesi Farmaceutici S.P.A. Sposób wytwarzania preparatu suchego proszku obejmującego środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
MX2020000435A (es) 2017-07-14 2020-08-17 Cytomx Therapeutics Inc Anticuerpos anti-cd166 y usos de estos.
CN111107788B (zh) * 2017-07-26 2023-12-19 深圳帧观德芯科技有限公司 具有空间扩展性x射线源的x射线成像系统
KR102576012B1 (ko) 2017-07-27 2023-09-07 알렉시온 파마슈티칼스, 인코포레이티드 고농도 항-c5 항체 제형
WO2019060604A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) * 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
WO2019060797A1 (en) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. PROCESS FOR PRODUCING POWDERS FOR INHALING
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
KR20200070355A (ko) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
ES2996257T3 (en) 2018-05-31 2025-02-12 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
KR20210071943A (ko) * 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
KR102784384B1 (ko) 2018-07-27 2025-03-21 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제를 위한 신규 담체 입자
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
MX2021004643A (es) 2018-10-30 2021-05-28 Chiesi Farm Spa Aparato para administrar farmacos a pacientes ventilados mecanicamente.
EA202191189A1 (ru) 2018-10-30 2021-08-06 Алексион Фармасьютикалс, Инк. Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг)
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
CN120025452A (zh) 2018-12-12 2025-05-23 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
EP4034079A1 (de) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Neuartige trägerpartikel für trockenpulverformulierungen zur inhalation
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
KR20230005268A (ko) 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
CN117425673A (zh) 2021-04-09 2024-01-19 武田药品工业株式会社 靶向补体因子d的抗体和其用途
JP2024518776A (ja) 2021-04-26 2024-05-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗ａｄｇｒｅ２抗体及びその使用
CN117545774A (zh) 2021-04-26 2024-02-09 米伦纽姆医药公司 抗clec12a抗体及其用途
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
CN118414147A (zh) 2021-12-21 2024-07-30 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN119947705A (zh) 2022-09-22 2025-05-06 奇斯药制品公司 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1571629A (en) 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
ATE94801T1 (de) 1990-01-29 1993-10-15 Ciba Geigy Ag Verfahren und vorrichtung zur dosierung eines feinkoernigen pulvers.
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
CA2115444C (en) 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
AR015173A1 (es) * 1997-09-30 2001-04-18 Mortimer Tech Holdings Un procedimiento para el tratamiento de material particulado, en el cual particulas del material a ser tratado interactuan con particulas no estaticas deun segundo material, una mena calcinada que se obtiene mediante dicho procedimiento, un reactor para exponer particulas huesped a un fluido y un re
AP1342A (en) * 1998-03-16 2004-12-15 Nektar Therapeutics Aerosolized active agent delivery.
ES2192866T3 (es) 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
AU3409399A (en) * 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
DK1223915T3 (da) * 1999-10-29 2006-03-06 Nektar Therapeutics Törpulverpræparater med forbedret dispersivitet
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
WO2002000197A1 (en) * 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition

Also Published As

Publication number Publication date
HU230464B1 (hu) 2016-07-28
ATE339195T1 (de) 2006-10-15
DE60125344T2 (de) 2007-07-19
WO2001078695A3 (en) 2002-03-14
PL204251B1 (pl) 2009-12-31
NO20024973D0 (no) 2002-10-16
NZ521887A (en) 2004-06-25
EE05257B1 (et) 2010-02-15
DE60125344D1 (de) 2007-02-01
SI1719505T1 (sl) 2011-12-30
CN1424909A (zh) 2003-06-18
US20050201950A1 (en) 2005-09-15
WO2001078693A3 (en) 2002-01-17
JP2012255035A (ja) 2012-12-27
EP2272508A3 (de) 2012-01-18
ATE513542T1 (de) 2011-07-15
DK1274406T3 (da) 2007-01-22
MXPA02010218A (es) 2003-05-23
BR0110141A (pt) 2003-01-28
EP1276473A2 (de) 2003-01-22
EP1276472B1 (de) 2006-12-20
HU229270B1 (en) 2013-10-28
US20120308613A1 (en) 2012-12-06
TNSN01060A1 (fr) 2005-11-10
EP1719505A3 (de) 2007-07-18
IL152306A0 (en) 2003-05-29
CA2406119C (en) 2009-07-07
GB2363987A (en) 2002-01-16
DE60131265D1 (de) 2007-12-20
BR0110301A (pt) 2003-12-30
HU229797B1 (en) 2014-07-28
AU784719B2 (en) 2006-06-01
NO342999B1 (no) 2018-09-24
US8182791B2 (en) 2012-05-22
EP1274406B1 (de) 2006-09-13
PT1276472E (pt) 2007-02-28
EP1274406A2 (de) 2003-01-15
NO20110885L (no) 2002-12-17
KR20030069047A (ko) 2003-08-25
NO20024971L (no) 2002-12-17
SK14912002A3 (sk) 2003-03-04
DE60131265T2 (de) 2008-03-06
CZ301904B6 (cs) 2010-07-28
AU2001258343A1 (en) 2001-10-30
CY1107315T1 (el) 2012-11-21
HUP0300593A2 (hu) 2003-09-29
HUP0300490A2 (en) 2003-07-28
MY129384A (en) 2007-03-30
GB0109432D0 (en) 2001-06-06
EP1719505B1 (de) 2011-08-24
DK1276472T3 (da) 2007-04-16
PL358875A1 (en) 2004-08-23
NO336687B1 (no) 2015-10-19
EP2272508B1 (de) 2020-03-25
SK284248B6 (sk) 2004-12-01
PL358640A1 (en) 2004-08-09
MXPA02010213A (es) 2005-07-01
ATE377416T1 (de) 2007-11-15
PL359289A1 (en) 2004-08-23
NO20024980L (no) 2002-12-17
SI1274406T1 (sl) 2007-02-28
HUP1300117A2 (en) 2003-07-28
EP1276473B1 (de) 2007-11-07
EE200200593A (et) 2004-04-15
CA2405767A1 (en) 2001-10-25
PT1719505E (pt) 2011-10-24
NO20024971D0 (no) 2002-10-16
ES2272473T3 (es) 2007-05-01
EP2272508A2 (de) 2011-01-12
GB2363988A (en) 2002-01-16
US20030175214A1 (en) 2003-09-18
EP1719505A2 (de) 2006-11-08
NO20024973L (no) 2002-12-16
NO20024980D0 (no) 2002-10-16
ATE348603T1 (de) 2007-01-15
CZ20023437A3 (cs) 2003-02-12
CA2406119A1 (en) 2001-10-25
GB0109431D0 (en) 2001-06-06
NO332025B1 (no) 2012-05-29
PL204213B1 (pl) 2009-12-31
WO2001078694A2 (en) 2001-10-25
EP1829533A3 (de) 2007-10-31
EP1829533B1 (de) 2011-06-22
HUP0300593A3 (en) 2006-07-28
EP1276472A2 (de) 2003-01-22
DZ3315A1 (fr) 2001-10-25
MXPA02010212A (es) 2004-06-29
CA2406201C (en) 2011-03-22
WO2001078694A3 (en) 2002-03-14
AU4859501A (en) 2001-10-30
DK1719505T3 (da) 2011-12-05
PT1274406E (pt) 2007-01-31
SA01220062B1 (ar) 2006-11-05
WO2001078695A2 (en) 2001-10-25
WO2001078693A2 (en) 2001-10-25
US6884794B2 (en) 2005-04-26
PE20011227A1 (es) 2002-01-07
ATE521340T1 (de) 2011-09-15
CA2406201A1 (en) 2001-10-25
DE60123031T2 (de) 2007-03-08
JP2003530425A (ja) 2003-10-14
AU4858101A (en) 2001-10-30
MA26892A1 (fr) 2004-12-20
ES2275669T3 (es) 2007-06-16
US20030180227A1 (en) 2003-09-25
ES2292576T3 (es) 2008-03-16
BR0110139A (pt) 2002-12-31
EP1829533A2 (de) 2007-09-05
US7223748B2 (en) 2007-05-29
CA2405767C (en) 2011-07-05
HUP0300499A2 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
DE60123031D1 (de) Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
US6503481B1 (en) Compositions for aerosolization and inhalation
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
Yang et al. Drug delivery performance of the mometasone furoate dry powder inhaler
KR20010020346A (ko) 염분치료를 행하는 방법 및 약품의 제조 공정
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition